Study population characteristics
| Factor | Categories | CVD groups | |
|---|---|---|---|
| Non-HF CVD (reference) (n=2985) | HF (n=170) | ||
| Age | 50–59 | 534 (17.9) | 5 (2.9) |
| 60–69 | 954 (32) | 30 (17.6) | |
| 70–79 | 1034 (34.6) | 61 (35.9) | |
| 80> | 463 (15.5) | 74 (43.5 | |
| Mean age (SD) | 69.5 (9.5) | 77.0 (8.2) | |
| Gender | Women | 1623 (54.4) | 82 (48.2) |
| Deprivation quartiles* | Q1—least deprived | 714 (23.9) | 49 (28.8) |
| Q2 | 666 (22.3) | 45 (26.5) | |
| Q3 | 782 (26.2 | 44 (25.9) | |
| Q4—most deprived | 822 (27.5) | 32 (18.8) | |
Figures in brackets are the percentage of each factor category within the CVD groups.
All CVD groups are defined by patients who received a British National Formulary Chapter 2 (CVD) drug prescription over a 2-year time period (2000–2001). Two mutually exclusive groups in the 2-year time period (i)reference group = CVD drug and CVD diagnostic categories (other than HF) in the record review (ii) HF group = CVD drugs and HF diagnostic categories.
*(n=3154).
CVD, cardiovascular disease; HF, heart failure.